Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib ofEGFRmutant advanced lung adenocarcinoma-Reference-Cited by-同舟云学术

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib ofEGFRmutant advanced lung adenocarcinoma

Published:2015-03-30 Issue:14 Volume:6 Page:12783-12795
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Bria Emilio¹,Pilotto Sara¹,Amato Eliana²,Fassan Matteo²,Novello Silvia³,Peretti Umberto¹,Vavalà Tiziana³,Kinspergher Stefania¹,Righi Luisella³,Santo Antonio¹,Brunelli Matteo⁴,Corbo Vincenzo²,Giglioli Eliana⁴,Sperduti Isabella⁵,Milella Michele⁶,Chilosi Marco⁴,Scarpa Aldo²⁴,Tortora Giampaolo¹

Affiliation:

1. Department of Medicine, Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy

2. ARC-NET Center for Applied Research on Cancer, University and Azienda Ospedaliera Universitaria Integrata, Verona, Italy

3. Department of Oncology, University of Torino, A.O.U. San Luigi, Orbassano, Torino, Italy

4. Department of Pathology and Diagnostics, University and Azienda Ospedaliera Universitaria Integrata, Verona, Italy

5. Biostatistics, Regina Elena National Cancer Institute, Rome, Italy

6. Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study;Frontiers in Oncology;2024-07-09

2. Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF‐mutation status?;Thoracic Cancer;2024-02-16

3. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review;Annals of Oncology;2023-12

4. TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC;Frontiers in Bioscience-Landmark;2023-07-24

5. The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?;Lung Cancer;2023-07